Trial Profile
Efficacy and safety of simeprevir with pegylated interferon alfa and low dose of ribavirin for patients with chronic hepatitis C genotype 1 and low hemoglobin level
Status:
Not yet recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 03 Aug 2019
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 18 May 2016 New trial record